GlassScriptPhysician profile
Laith Altamimi
NPI 1457879488
$4,991.55
in general payments reported to CMS, 2019-2025
37 companies · $985 in 2025
The $985 reported for 2025 was more than what 85% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,675 · 2022: $867 · 2023: $934 · 2024: $530 · 2025: $985.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,661 · Education: $489 · Long Term Medical Supply Or Device Loan: $299.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,661.47 |
| Education | $488.94 |
| Long Term Medical Supply Or Device Loan | $299.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $846.90 | 2021-2025 | Xospata, Cresemba |
| Novartis Pharmaceuticals Corporation | $755.47 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $347.56 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $321.82 | 2021-2025 | Tagrisso, Lynparza, Imfinzi |
| Genzyme Corporation | $297.90 | 2021-2025 | |
| Janssen Biotech, INC. | $227.94 | 2021-2025 | Tecvayli, Darzalex, Carvykti |
| Seagen INC. | $206.41 | 2021-2025 | |
| Daiichi Sankyo INC. | $177.15 | 2021-2025 | Injectafer, Vanflyta |
| Amgen INC. | $171.95 | 2021-2022 | |
| Lilly USA, LLC | $165.28 | 2021 | |
| Incyte Corporation | $159.70 | 2021-2023 | Jakafi, Monjuvi |
| Exelixis INC. | $134.98 | 2021-2025 | Cabometyx |
| Glaxosmithkline, LLC. | $129.53 | 2021-2022 | |
| Puma Biotechnology, INC. | $124.17 | 2021 | |
| Janssen Scientific Affairs, LLC | $103.25 | 2022 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacyclics LLC, An Abbvie Company | $89.53 | 2021 | |
| Pfizer INC. | $81.82 | 2021-2025 | |
| Dova Pharmaceuticals | $72.10 | 2021 | |
| Gilead Sciences, INC. | $54.47 | 2021-2025 | |
| Eisai INC. | $50.97 | 2021-2025 | |
| Genentech USA, INC. | $40.11 | 2022-2023 | Tecentriq |
| Merck Sharp & Dohme LLC | $39.68 | 2021-2024 | Lynparza, Keytruda |
| Kite Pharma, INC. | $39.37 | 2021 | |
| Morphosys, US INC. | $37.33 | 2021 | |
| Taiho Oncology, INC. | $34.13 | 2021 | |
| Springworks Therapeutics, INC. | $33.58 | 2025 | Ogsiveo |
| Tersera Therapeutics LLC | $31.42 | 2025 | Zoladex |
| Ipsen Biopharmaceuticals, INC | $29.57 | 2025 | Onivyde |
| Biocon Biologics INC | $28.01 | 2025 | Ogivri |
| Pharmaessentia USA Corporation | $25.10 | 2025 | Besremi |
| Abbvie INC. | $24.02 | 2025 | |
| Alexion Pharmaceuticals, INC. | $21.06 | 2021 | |
| Pharmacosmos Therapeutics INC. | $20.52 | 2022 | |
| Sobi, INC | $20.20 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.29 | 2025 | Fruzaqla |
| Coherus Oncology, INC. | $15.40 | 2021 | |
| Blueprint Medicines Corporation | $14.86 | 2025 | Ayvakit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laith Altamimi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.